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INTRODUCTION
Preeclampsia, a pregnancy-specific syndrome affecting
about 5% to 10% of pregnancies, is characterized by the
presence of hypertension and proteinuria. This syndrome is
one of the leading causes of maternal and fetal morbidity
and mortality worldwide and occurs only in the presence of
a placenta and remits dramatically after the placenta has been
delivered. Although the exact pathogenesis of preeclampsia
remains unclear, it has been suggested that endothelial dys-
function may play a central role in the development of pree-
clampsia. Impaired trophoblastic invasion of the maternal
placental bed is considered to be the initial event of endothe-
lial dysfunction in preeclampsia. Consequently, reduction of
uteroplacental blood perfusion by shallow implantation results
in local placental hypoxia. A hypoxic/ischemic placenta may
then release placental factors into the maternal circulation
eventually causing endothelial dysfunction, which leads to
the main clinical symptoms of preeclampsia (including hyper-
tension and proteinuria).
A role of the balance between soluble fms-like tyrosine
kinase (sFlt-1) and placental growth factor (PlGF) in the pa-
thogenesis of preeclampsia has been proposed by several inves-
tigators (1-4). sFlt-1 is a secreted splice variant of Flt-1 that
antagonizes vascular endothelial growth factor (VEGF) and
PlGF by binding, and prevents their interaction with endo-
thelial receptors on the cell surface (5). PlGF is a secreted
dimeric glycoprotein that possesses potent angiogenic and
mitogenic activities capable of inducing the proliferation,
migration, and activation of endothelial cells (6, 7). It has
been recently shown that increased sFlt-1 occurs approxima-
tely five to six weeks before the onset of clinical symptoms
of preeclampsia (1, 2), whereas decreased PlGF levels are ob-
served prior to 20 weeks of gestation in women who subse-
quently develop preeclampsia (3, 4). Moreover, administra-
tion of exogenous sFlt-1 to pregnant rats leads to reduced
PlGF, hypertension, proteinuria, and glomerular endothelial
injury (8). Therefore, the pathogenesis of preeclampsia may
involve an imbalance of angiogenic factors, and the mea-
surement of sFlt-1 in combination with PlGF may distin-
guish women who subsequently develop preeclampsia from
women who remain normotensive during pregnancy (8).
In this study we investigated whether the second trimester
plasma levels of sFlt-1 and PlGF were altered in women who
subsequently developed preeclampsia.
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Increased sFlt-1 to PlGF Ratio in Women Who Subsequently Develop
Preeclampsia
The purpose of this study was to determine whether the levels of soluble fms-like
tyrosine kinase-1 (sFlt-1) and placenta growth factor (PlGF) are altered during the
second trimester in the plasma of women who subsequently develop preeclamp-
sia. We performed a case-control study to compare the levels of sFlt-1 and PlGF in
the preeclamptic (n=46) and normal pregnant women (n=100). The maternal plas-
ma levels of sFlt-1 and PlGF were measured by enzyme-linked immunosorbent
assay. The sFlt-1 levels were significantly higher in the preeclamptic women than in
normal controls (p<0.001), while the PlGF levels were significantly lower (p<0.001).
In normal controls, sFlt-1 levels were positively correlated (r=0.27, p=0.008), where-
as, in the preeclamptic women, those were negatively correlated with the PlGF
levels (r=-0.423, p=0.005). Furthermore, the log[sFlt-1/PlGF] ratio was significantly
higher in the preeclamptic women than in normal controls (p<0.001). The receiver
operating characteristic curve revealed a specificity of 78% with a diagnostic sen-
sitivity of 80.4%; the optimal cut-off value of the log[sFlt-1/PlGF] ratio was 1.4 (95%
CI 0.756-0.910, p<0.001). Preeclampsia showed a strong association with increas-
ed levels of sFlt-1 and decreased levels of PlGF in the second trimester maternal
plasma. Accordingly, the sFlt-1/PlGF ratio may provide early prediction of subse-
quent development of preeclampsia.
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MATERIALS AND METHODS
Subjects
Subjects were recruited from the Obstetrics and Gynecol-
ogy Department at Cheil General Hospital between Octer-
ber 2001 and December 2003. The study subjects included
46 women who subsequently developed preeclampsia (17
with mild preecalmpsia and 29 with severe preeclampsia)
and 100 women with normal pregnancies who were matched
for race, maternal age, and gestational age at the time of
blood sampling. Preeclampsia was defined as hypertension
(systolic blood pressure ≥140 mmHg and diastolic blood
pressure ≥90 mmHg after 20 weeks gestation) and pro-
teinuria (≥300 mg in a 24 hr urine collection or ≥1+ on
dipstick testing). Exclusion criteria included major congen-
ital anomalies, fetal chromosomal abnormalities, multiple
pregnancies, chronic hypertension, diabetes mellitus, and
renal disease. Control subjects were selected randomly from
women who were normotensive and without proteinuria
throughout pregnancy and who delivered a healthy neonate
at term without significant medical or obstetric complica-
tions such as; chronic hypertension, diabetes, renal insuffi-
ciency, congenital anomalies or fetal demise. This study was
approved by the Ethics Committee at Cheil General Hospi-
tal, and written informed consent was obtained from all
enrolled women.
Samples and immunoassay
Maternal blood was obtained at 14 to 23 weeks of gesta-
tion and was collected into heparinized vacutainer tubes.
Maternal plasma samples were isolated by 2,500 g centrifu-
gation for 10 min. Aliquots of maternal plasma were stored at
-70℃ until analysis. Levels of sFlt-1 and PlGF in maternal
plasma were measured with a commercially available en-
zyme-linked immunosorbent assay (ELISA, R&D System,
Minneapolis, MN, U.S.A.) according to the manufacture’s
instructions. All samples were examined in duplicate, and
the mean values of individual samples were used for statisti-
cal analysis. The minimal detectable levels in the assays of
sFlt-1 and PlGF were 5.0 and 7.0 pg/mL, respectively. The
inter- and intra-assay coefficients of variation were 3.8%
and 7.0% for sFlt-1 and 3.6% and 11.0% for PlGF, respec-
tively.
Statistical analysis
All data are presented as the median (range) and number
(percentage). Data not normally distributed were analyzed
by nonparametric tests. A comparison of continuous variables
between the two groups was performed using the Student’s
t test or Mann-Whitney U test, and proportions were com-
pared with the  2 test or Fisher’s exact test. Spearman’s rank
correlation was used to assess the relationship between the
two variables. Receiver operating characteristic (ROC) analy-
sis was performed to assess the best cut-off value and discri-
minating capacity of the log[sFlt-1/PlGF] ratios in the sec-
ond trimester plasma for predicting women who subsequ-
ently developed preeclampsia. Sensitivity, specificity, and odds
ratio (OR) with 95% confidence intervals (CI) were calculat-
ed in order to consider the predictive efficacy of the log[sFlt-
1/PlGF] ratio. Statistical analysis was performed with the
Statistical Package for Social Sciences version 10.0 (SPSS Inc.,
Chicago, IL, U.S.A.). A p value <0.05 was considered statis-
tically significant.
RESULTS
The clinical characteristics of the study population are
shown in Table 1. There were no significant differences in
maternal age, gestational age at blood sampling, or platelet
count between the preeclamptic and normal pregnant wo-
men. As expected, systolic and diastolic blood pressures
were significantly higher in the preeclamptic women than
in normal controls. By contrast, nulliparity, gestational age
at delivery, and birth weight were lower in the preeclamptic
women than in the normal controls.
Maternal plasma sFlt-1 levels were significantly higher in
the preeclamptic women than in normal controls (median
3,861, range 1,389-15,915 vs. median 2,353, range 1,071-
6,898, p<0.001) (Fig. 1A). The levels of maternal plasma
PlGF levels were significantly lower in the preeclamptic wo-
men than in normal controls (median 86, range 29-232 vs.
median 146, range 68-380, p<0.001) (Fig. 1B). Fig. 2 pre-
sents the correlation between the plasma sFlt-1 and PlGF
levels in the two groups. In the preeclamptic women, there
was a significant negative correlation between the plasma
Values are expressed as median (range) or number (%).
*Statistically significant, p<0.05.
Normal pregnancy
(n=100)
Characteristics
Preeclampsia 
(n=46)
p value
Maternal age (yr) 35 (22-46) 34 (26-40) 0.313
Nulliparity* 52 (52) 32 (69.6) 0.046
Gestational age at  16.6 (15-23) 17.2 (14.3-19.6) 0.120
sampling (wk)
Gestational age at  39 (35.4-41.1) 37.1 (27.1-41.3) <0.001
delivery (wk)*
Systolic blood pressure  125 (108-139) 148 (110-192) <0.001
(mmHg)*
Diastolic blood pressure  74 (60-97) 96 (70-117) 0.005
(mmHg)*
Birth weight (g)* 3362.5  2627.5 <0.001
(2,095-4,555) (744-3,830)
Platelet count (×10
3)  230 (122-384) 267 (156-408) 0.075
( /L)
Table 1. Clinical characteristics of the study populationPlasma sFlt-1/PlGF Ratio in Preeclampsia 875
sFlt-1 and PlGF levels (r=-0.423, p=0.005), whereas there
was a significant positive correlation between these variables
in normal controls (r=0.270, p=0.008). We also evaluated
the ratio of log[sFlt-1/PlGF] in the maternal plasma of the
preeclamptic women and normal controls. The plasma log
[sFlt-1/PlGF]ratio was significantly higher in the preeclamp-
tic women than in normal controls (median 1.6, range 1.0-
2.9 vs. median 1.2, range 0.5-1.9, p<0.001) (Fig. 3). The
maternal plasma log[sFlt-1/PlGF] ratio with the cut-off
value of 1.4 provided the best combination with 80.4%
sensitivity and 78% specificity (area under the curve [95%
CI]: 0.833 [0.756-0.910], p<0.001) (Fig. 4). Women with
the maternal plasma log[sFlt-1/PlGF] ratio of >1.4 had an
increased risk of subsequently developing preeclampsia (OR
[95% CI]: 17.0 [7.3-39.5], p<0.001).
DISCUSSION
We found a decreased level of PlGF and an increased level
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Fig. 1. Box plots indicating levels of sFlt-1 (A) and PlGF (B) in maternal plasma between normal controls and preeclamptic women. Boxes
denote the interquartile range with the upper and lower horizontal edges representing the 75th and 25th percentiles, respectively. The
central horizontal lines represent the medians. The vertical whiskers above and below the boxes represent the range of outlying data
points up to 1.5 times the interquartile range, and the circles beyond the whiskers represent severe outliers. *Statistically significant, p<0.05. 
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Fig. 2. Correlation between sFlt-1 and PlGF levels in maternal plas-
ma of the preeclamptic women (    ) and normal controls (    ). The
solid and dashed lines indicate the regression lines for the pree-
clamptic women and normal controls, respectively.
Control
Fig. 3. Box plots indicating ratios of the log[sFlt-1/PlGF] in mater-
nal plasma between normal controls and preeclamptic women.
Boxes denote the interquartile range with the upper and lower hor-
izontal edges representing the 75th and 25th percentiles, respec-
tively. The central horizontal lines represent the medians. The ver-
tical whiskers above and below the boxes represent the range of
outlying data points up to 1.5 times the interquartile range, and
the circles beyond the whiskers represent severe outliers. *Sta-
tistically significant, p<0.05.
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of sFlt-1 in the second trimester plasma of women who sub-
sequently developed preeclampsia compared to normal preg-
nant women. Moreover, PlGF levels of the normal controls
were positively correlated, while those of the preeclamptic
women were negatively correlated with sFlt-1 levels. Our
data also revealed that the sFlt-1/PlGF ratio in the preeclamp-
tic women was significantly higher compared to normal
controls. We speculated that preeclampsia may be secondary
to endothelial dysfunction caused by the imbalance of circu-
lating angiogenic factors of placental origin, such as sFlt-1
and PlGF. Further analysis will be required to clarify the regu-
lation of angiogenic factors and their secretion in the women
with preeclampsia as well as the role of angiogenic factors in
the pathophysiology of preeclampsia.
Our data regarding both sFlt-1 and PlGF levels are con-
sistent with the previous studies of Chaiworapongsa et al.
(9) and Koga et al. (10) who found elevated plasma/serum
concentrations of sVEGFR-1 in patients with preeclampsia
at the time of diagnosis. In addition, the placentas from pree-
clamptic women have been shown to produce higher con-
centrations of sFlt-1 in vitro compared to normal controls
(11, 12). Excess placental sFlt-1 may contribute to endothe-
lial dysfunction, hypertension, and proteinuria in preeclamp-
sia (3, 8). Several studies have documented that beginning
in the early second trimester, and as early as 10 to 11 weeks
of gestation, the plasma/serum PlGF concentration in women
who go on to develop preeclampsia is lower than in normoten-
sive controls (13-16).
The results of current studies suggest that the identifica-
tion of high concentrations of sFlt-1 combined with low
concentrations of PlGF may be used to predict the develop-
ment of preeclampsia several weeks in advance of clinical
onset of symptoms (1, 3, 17). Levine et al. (1) reported that the
increase of sFlt-1 corresponds to a decrease of free PlGF in
the serum of patients with preeclampsia resulting in endothe-
lial dysfunction. Their results revealed that preeclampsia is
associated with increased sFlt-1 concentrations in pregnant
women five weeks before clinical disease and also with de-
creased PlGF from 13 to 16 weeks of gestation (1). Further-
more, the combination of first-trimester maternal serum
concentrations of sFlt-1 (high) and PlGF (low) clearly iden-
tifies women at high risk of subsequent preeclampsia (3).
The combination of both serum PlGF and sFlt-1 distin-
guished women who subsequently developed preeclampsia
from those who subsequently developed gestational hyper-
tension, delivered SGA (small for gestational age) newborns
or completed a normal-term pregnancy (17). 
Some investigators have suggested that the sFlt-1/PlGF
ratio may be predictive of preeclampsia risk (1). In the pre-
sent study, we evaluated the preeclampsia risk in relation-
ship to the sFlt-1/PlGF ratio. In agreement with previous
reports, preeclamptic women in our study had a higher sFlt-
1/PlGF ratio compared to the normal controls. In addition,
a recent study has demonstrated that severe preeclampsia is
associated with increased urinary output of sFlt-1 and a de-
creased output of PlGF at the time of clinical manifestation
(18). Therefore, rapid noninvasive screening of hypertensive
women based on the Flt-1/PlGF ratio may be used to define
the severity of preeclampsia (18). These findings suggest that
alteration of sFlt-1 and PlGF levels may be important in the
pathophysiology of preeclampsia.
The mechanisms responsible for the alternation of mater-
nal plasma sFlt-1 and PlGF concentrations in women with
preeclampsia remain unknown. In vitro studies have shown
that PlGF is decreased (19) and sFlt-1 is increased (20) in
trophoblast cells under conditions of reduced oxygen tension.
It appears that PlGF deficiency and sFlt-1 excess may result
from placental hypoxia associated with incomplete remodel-
ing of maternal spiral arteries. The incompletely remodeled
arteries offer persistently high resistance to uterine artery
blood flow, and they may be predisposed to vascular rupture
in the placental bed, especially after the onset of hyperten-
sion (21, 22). However, there is still not enough evidence to
support the notion that altered levels of these angiogenic
factors in maternal plasma of preeclamptic women are the
consequence or the cause of a placentation deficit. Further-
more, the specific role of sFlt-1 and PlGF in the physiologic
and pathologic development of placentation requires further
investigation. 
In summary, our results showed that sFlt-1 levels were
increased and PlGF levels were decreased in second trimester
plasma of women who subsequently developed preeclamp-
sia compared to the normal pregnant women, and that a
negative correlation existed between the circulating sFlt-1
and PlGF levels in the preeclamptic women. We also found
that sFlt-1/PlGF ratios were significantly higher in women
Fig. 4. Receiver operating characteristic curve (ROC) showing
the ability of the maternal plasma log[sFlt-1/PlGF] to differentiate
preeclampsia from normal pregnancies. AUC, area under the
curve.
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AUC: 0.833with preeclampsia than in normal controls. Although sFlt-1
and PlGF have been shown to be associated with preeclamp-
sia and may be potential markers for the early prediction of
preeclampsia before clinical manifestations are identified,
further prospective, large-scale, longitudinal studies are essen-
tial to determine the usefulness of sFlt-1 and PlGF in pre-
dicting preeclampsia.
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